140 related articles for article (PubMed ID: 2960897)
1. A randomized trial of intravenous tissue plasminogen activator for acute myocardial infarction with subsequent randomization to elective coronary angioplasty.
Guerci AD; Gerstenblith G; Brinker JA; Chandra NC; Gottlieb SO; Bahr RD; Weiss JL; Shapiro EP; Flaherty JT; Bush DE
N Engl J Med; 1987 Dec; 317(26):1613-8. PubMed ID: 2960897
[TBL] [Abstract][Full Text] [Related]
2. Comparison of invasive and conservative strategies after treatment with intravenous tissue plasminogen activator in acute myocardial infarction. Results of the thrombolysis in myocardial infarction (TIMI) phase II trial.
TIMI Study Group
N Engl J Med; 1989 Mar; 320(10):618-27. PubMed ID: 2563896
[TBL] [Abstract][Full Text] [Related]
3. A randomized trial of immediate versus delayed elective angioplasty after intravenous tissue plasminogen activator in acute myocardial infarction.
Topol EJ; Califf RM; George BS; Kereiakes DJ; Abbottsmith CW; Candela RJ; Lee KL; Pitt B; Stack RS; O'Neill WW
N Engl J Med; 1987 Sep; 317(10):581-8. PubMed ID: 2956516
[TBL] [Abstract][Full Text] [Related]
4. A comparison of immediate angioplasty with thrombolytic therapy for acute myocardial infarction. The Primary Angioplasty in Myocardial Infarction Study Group.
Grines CL; Browne KF; Marco J; Rothbaum D; Stone GW; O'Keefe J; Overlie P; Donohue B; Chelliah N; Timmis GC
N Engl J Med; 1993 Mar; 328(10):673-9. PubMed ID: 8433725
[TBL] [Abstract][Full Text] [Related]
5. A randomized, placebo-controlled trial of intravenous recombinant tissue-type plasminogen activator and emergency coronary angioplasty in patients with acute myocardial infarction.
Topol EJ; O'Neill WW; Langburd AB; Walton JA; Bourdillon PD; Bates ER; Grines CL; Schork AM; Kline E; Pitt B
Circulation; 1987 Feb; 75(2):420-8. PubMed ID: 2948735
[TBL] [Abstract][Full Text] [Related]
6. Evaluation of combination thrombolytic therapy and timing of cardiac catheterization in acute myocardial infarction. Results of thrombolysis and angioplasty in myocardial infarction--phase 5 randomized trial. TAMI Study Group.
Califf RM; Topol EJ; Stack RS; Ellis SG; George BS; Kereiakes DJ; Samaha JK; Worley SJ; Anderson JL; Harrelson-Woodlief L
Circulation; 1991 May; 83(5):1543-56. PubMed ID: 1902405
[TBL] [Abstract][Full Text] [Related]
7. Intravenous tissue plasminogen activator and size of infarct, left ventricular function, and survival in acute myocardial infarction.
Van de Werf F; Arnold AE
BMJ; 1988 Nov; 297(6660):1374-9. PubMed ID: 3146370
[TBL] [Abstract][Full Text] [Related]
8. A double blind placebo controlled study of early and late administration of recombinant tissue plasminogen activator in acute myocardial infarction.
McNeill AJ; Cunningham SR; Flannery DJ; Dalzell GW; Wilson CM; Campbell NP; Khan MM; Patterson GC; Webb SW; Adgey AA
Br Heart J; 1989 Apr; 61(4):316-21. PubMed ID: 2496740
[TBL] [Abstract][Full Text] [Related]
9. A randomized trial comparing primary angioplasty with a strategy of short-acting thrombolysis and immediate planned rescue angioplasty in acute myocardial infarction: the PACT trial. PACT investigators. Plasminogen-activator Angioplasty Compatibility Trial.
Ross AM; Coyne KS; Reiner JS; Greenhouse SW; Fink C; Frey A; Moreyra E; Traboulsi M; Racine N; Riba AL; Thompson MA; Rohrbeck S; Lundergan CF
J Am Coll Cardiol; 1999 Dec; 34(7):1954-62. PubMed ID: 10588209
[TBL] [Abstract][Full Text] [Related]
10. Variables predictive of good functional outcome following thrombolytic therapy in the Thrombolysis in Myocardial Infarction phase II (TIMI II) pilot study.
Rogers WJ; Bourge RC; Papapietro SE; Wackers FJ; Zaret BL; Forman S; Dodge HT; Robertson TL; Passamani ER; Braunwald E
Am J Cardiol; 1989 Mar; 63(9):503-12. PubMed ID: 2521976
[TBL] [Abstract][Full Text] [Related]
11. A new thrombolytic regimen for acute myocardial infarction using combination half dose tissue-type plasminogen activator with full dose streptokinase: a pilot study. KAMIT Study Group.
Grines CL; Nissen SE; Booth DC; Branco MC; Gurley JC; Bennett KA; DeMaria AN
J Am Coll Cardiol; 1989 Sep; 14(3):573-80. PubMed ID: 2504797
[TBL] [Abstract][Full Text] [Related]
12. A multicenter, randomized, placebo-controlled trial of a new form of intravenous recombinant tissue-type plasminogen activator (activase) in acute myocardial infarction.
Topol EJ; Morris DC; Smalling RW; Schumacher RR; Taylor CR; Nishikawa A; Liberman HA; Collen D; Tufte ME; Grossbard EB
J Am Coll Cardiol; 1987 Jun; 9(6):1205-13. PubMed ID: 2953770
[TBL] [Abstract][Full Text] [Related]
13. Effect of intravenous streptokinase as compared with that of tissue plasminogen activator on left ventricular function after first myocardial infarction.
White HD; Rivers JT; Maslowski AH; Ormiston JA; Takayama M; Hart HH; Sharpe DN; Whitlock RM; Norris RM
N Engl J Med; 1989 Mar; 320(13):817-21. PubMed ID: 2494454
[TBL] [Abstract][Full Text] [Related]
14. Thrombolysis with intravenous human recombinant tissue-type plasminogen activator in acute myocardial infarction: the European experience.
de Bono DP
J Am Coll Cardiol; 1987 Nov; 10(5 Suppl B):75B-78B. PubMed ID: 2959717
[TBL] [Abstract][Full Text] [Related]
15. [Intravenous infusion of recombinant tissue-type plasminogen activator (rt-PA) and urokinase in acute myocardial infarct: intermediate results of the G.A.U.S. study (German Activator Urokinase Study)].
Neuhaus KL; Tebbe U; Gottwik M; Weber MA; Feuerer W; Niederer W; Haerer W; Praetorius F; Grosser KD; Huhmann W
Klin Wochenschr; 1988; 66 Suppl 12():102-8. PubMed ID: 3126339
[TBL] [Abstract][Full Text] [Related]
16. Immediate vs delayed catheterization and angioplasty following thrombolytic therapy for acute myocardial infarction. TIMI II A results. The TIMI Research Group.
JAMA; 1988 Nov; 260(19):2849-58. PubMed ID: 2972848
[TBL] [Abstract][Full Text] [Related]
17. A comparison between heparin and low-dose aspirin as adjunctive therapy with tissue plasminogen activator for acute myocardial infarction. Heparin-Aspirin Reperfusion Trial (HART) Investigators.
Hsia J; Hamilton WP; Kleiman N; Roberts R; Chaitman BR; Ross AM
N Engl J Med; 1990 Nov; 323(21):1433-7. PubMed ID: 2122251
[TBL] [Abstract][Full Text] [Related]
18. Emergency coronary artery bypass surgery preserves global and regional left ventricular function after intravenous tissue plasminogen activator therapy for acute myocardial infarction.
Kereiakes DJ; Topol EJ; George BS; Abbottsmith CW; Stack RS; Candela RJ; O'Neill WW; Martin LH; Califf RM
J Am Coll Cardiol; 1988 May; 11(5):899-907. PubMed ID: 2965716
[TBL] [Abstract][Full Text] [Related]
19. The Thrombolysis in Myocardial Infarction (TIMI) phase II pilot study: tissue plasminogen activator followed by percutaneous transluminal coronary angioplasty.
Passamani E; Hodges M; Herman M; Grose R; Chaitman B; Rogers W; Forman S; Terrin M; Knatterud G; Robertson T
J Am Coll Cardiol; 1987 Nov; 10(5 Suppl B):51B-64B. PubMed ID: 2889758
[TBL] [Abstract][Full Text] [Related]
20. A prospective, randomized trial comparing combination half-dose tissue-type plasminogen activator and streptokinase with full-dose tissue-type plasminogen activator. Kentucky Acute Myocardial Infarction Trial (KAMIT) Group.
Grines CL; Nissen SE; Booth DC; Gurley JC; Chelliah N; Wolf R; Blankenship J; Branco MC; Bennett K; DeMaria AN
Circulation; 1991 Aug; 84(2):540-9. PubMed ID: 1907228
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
